Andreas Calatzis

PhD, MD

Chairman

Leader in the development, manufacturing, and marketing of widely used IVD analyzers: ROTEM (acquired by Werfen, 2016); Multiplate (acquired by Roche, 2012); and ClotPro (acquired by Haemonetics, 2020); Worked for Roche Diagnostics for 5 years. Previously Managing Director at Verum Diagnostica.

Pablo Cironi

PhD

Director of Life Science Investment Funds at Caixa Capital Risc

Pablo Cironi is the Director of Life Science Investment Funds at Caixa Capital Risc. He focuses on investment in therapeutics and medical devices. He currently serves on the Board of Directors at Medlumics, Aelix Therapeutics, Minoryx Therapeutics, iProteos, Proteodesign, Laboratoris Sanifit and GlyCardial Diagnostics. Pablo has more than 12 years of experience in business development, technology transfer and in early stage investment. Pablo graduated in Chemistry from the University of Buenos Aires and holds a Ph.D. in Organic Chemistry from the University of Barcelona. From 2005 to 2009, he was a postdoctoral Fulbright Fellow at the Department of Systems Biology at Harvard University.

Albert Ferrer

MBA

Director Healthequity SCR; Partner at Invivo Capital

Degree in Business Administration and MBA from ESADE, Master CEMS (Community of European Management Schools) in Management from HEC – Hautes Études Commerciales (París) and Chartered Financial Analyst (CFA).

He has been involved in the Spanish VC industry for the past 20 with a focus on high-growth, early stage, technology centered investments.

He is currently Director of Healthequity, a venture capital fund focused in early-stage companies in the healthcare sector, where he led the investment strategy and transaction processes of the different portfolio companies. He has been a member of the Board of Directors of different life-sciences companies and of Healthequity's investments: Sanifit, Peptomyc and Glycardial Diagnostics.

Co-founder of the managing company Invivo Capital Partners, where he is member of the board of directors of different portfolio companies: Arthex, Pumobiotics, Gyala, Telum, OneChain Immunotherapeutics and Telomere Therapeutics.

Previously, he led Spinnaker Invest, VC firm within Grupo Financiero Riva y García. He has been as well a member of the Board of Directors of various companies such as Exoticca, Wecare-u and Scytl.

Judit Cubedo

PhD, MBA

Co-Founder and Chief Executive Officer (CEO)

Dr. Cubedo holds a PhD in Molecular and Cellular Biology from the University of Barcelona and an MBA from La Salle University. She has solid expertise in biomarker discovery, gained from 12 years spent conducting several research lines on clinical differential proteomic studies, biomarker validation studies and the characterization of protein post-translational modifications, for the identification of new biomarkers of cardiovascular risk and its clinical manifestations.

She has published more than 37 scientific publications in high-impact journals, including original papers and reviews, and two book chapters, and she holds four patents. She has participated in more than 10 research projects. She has been representative of the Scientist of Tomorrow (SoT) in the Working Group on Coronary Pathophysiology and Microcirculation (WG6) of the European Society of Cardiology (ESC), member of the Young Thrombosis Researchers Group of the ESC, and member of the Spanish Research Network for Cardiovascular Disease (RIC). During her last years in academic research her work was addressed to the development of immunobased assays for the detection of novel potential biomarkers of cardiovascular disease with transfer and commercialization potential. She was awarded with the Innovators Under 35-Spain MIT Technology Review award for the development of the first prototype to quantify ApoJ-Glyc as a biomarker of ischemia.

As CEO of GlyCardial, she has leaded critical stages such as the technology transfer process from the Institution into the Company, the incorporation of GlyCardial Diagnostics and the raising of more than 5M€ in private and public funding in the first 3 years of the company.

Dr. Cubedo has participated in several programs of entrepreneurship including CaixaImpulse and CaixaStart (La Caixa Banking Foundation) and the Acceleration programme of social impact projects Tech4Health (Ship2b Foundation). In 2020 she was listed among the 21 Women Innovators by the European Commission (EU Prize for Women Innovators).

Lina Badimon

PhD

Co-Founder and Chief Scientific Officer (CSO)

Director of the ICCC Program and CSIC-Professor, at the IR-Hospital de la Santa Creu i Sant Pau-Universidad Autónoma de Barcelona, Instituto de Investigaciones Biomédicas IIB-SPau; “Lecturer Adjunt Associate Professor” of Medicine – Cardiology – at Mount Sinai School of Medicine, New York (USA), Director of Catalana Occidente Chair -UAB, Director of “UNESCO Chair in Biomedical Sciences Training and Research” and Vicepresident of Scientific Affairs of the “European Society of Cardiology” (ESC).

Her research interest is centred on cardiovascular and cardiometabolic disease, atherosclerosis, thrombosis and ischemic diseases. She has published over 660 articles in highly rated scientific journals and her work has been highly cited in the scientific literature (H-index 88). She has written more than 240 review articles/book chapters. She is co-author of 9 patents. Her previous professional assignments include: “Postdoctoral Fellow” (1981-1983) Division of Cardiovascular Diseases at the Mayo Clinic, Rochester, MN, USA; Director of Research at the Division of Cardiology in the Mount Sinai Medical Center in New York (1983-1991), “Assistant Professor of Medicine” (1983-1987) and “Associate Professor of Medicine” (1988-1991) in Mount Sinai School of Medicine, NY; “Lecturer in Medicine” at Harvard Medical School and “Consultant” at the Cardiac Unit of the Massachusetts General Hospital de Boston (1992-1994).

Her scientific positions of trust include: Vice-President of the Sociedad Española de Cardiología (2014-2016); Chair of the Council on Basic Cardiovascular Science (2014-2016), Past-Chair of the Working Group on Coronary Pathophysiology and Microcirculation (2014-2016) and Past-Chair of the Working Group on Thrombosis (2002-2004) of the “European Society of Cardiology”; President of the European Society for Clinical Investigation (2000-2002); President of the Sociedad Española de Arteriosclerosis (1996-2000). During her career she has received several awards and honours such as: Fellow of the “Cardiovascular Science Council” and of the “Atherosclerosis, Thrombosis and Vascular Biology Council” of the American Heart Association; Fellow of the European Society of Cardiology; Distinguished Fellow of the International Atherosclerosis Society; Honorary Member of the Romanian Society of Hypertension and of the Hungarian Society of Cardiology. Rey Jaime I Award-2014 on Clinical Research. Doctor Honoris Causa by the Carol Davila University of Medicine and Pharmacy (Bucarest, Romania).